BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) Director Bihua Chen purchased 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was bought at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the purchase, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. This represents a 9.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
BlossomHill Therapeutics Stock Performance
Shares of BlossomHill Therapeutics stock traded down $0.01 on Monday, hitting $15.99. 417,968 shares of the company traded hands. BlossomHill Therapeutics, Inc. has a 12-month low of $15.25 and a 12-month high of $17.25.
Recommended Stories
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
